Mind Medicine Company Insiders
| MNMD Stock | USD 6.31 0.14 2.17% |
Mind Medicine employs about 74 people. The company is managed by 15 executives with a total tenure of roughly 173 years, averaging almost 11.0 years of service per executive, having 4.93 employees per reported executive. Evaluation of Mind Medicine's management performance can provide insight into the firm performance.
Mind |
Mind Medicine Management Team Effectiveness
The company has return on total asset (ROA) of (0.3044) % which means that it has lost $0.3044 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6801) %, meaning that it created substantial loss on money invested by shareholders. Mind Medicine's management efficiency ratios could be used to measure how well Mind Medicine manages its routine affairs as well as how well it operates its assets and liabilities.Mind Medicine Workforce Comparison
Mind Medicine is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,389. Mind Medicine holds roughly 74.0 in number of employees claiming about 5% of equities under Health Care industry.
Mind Medicine Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mind Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mind Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Mind Medicine insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mind Medicine Notable Stakeholders
A Mind Medicine stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mind Medicine often face trade-offs trying to please all of them. Mind Medicine's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mind Medicine's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Miriam Wernli | Executive President | Profile | |
| BA MA | Executive President | Profile | |
| CGMA CPA | VP Officer | Profile | |
| MD MA | Chief Officer | Profile | |
| Schond MBA | Chief Officer | Profile | |
| Maxim CFA | Vice Communications | Profile | |
| Wong JD | Chief Sec | Profile | |
| Gregg Pratt | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Mark JD | Chief Secretary | Profile | |
| Scott MD | CoFounder Advisor | Profile | |
| Stephanie Fagan | Chief Officer | Profile | |
| Leonard Latchman | Cofounder | Profile | |
| Schond Greenway | Chief Officer | Profile | |
| Robert Barrow | CEO Director | Profile |
About Mind Medicine Management Performance
The success or failure of an entity such as Mind Medicine often depends on how effective the management is. Mind Medicine management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mind management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mind management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Mind Medicine Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. Mind Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Please note, the presentation of Mind Medicine's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mind Medicine's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mind Medicine's management manipulating its earnings.
Mind Medicine Workforce Analysis
Traditionally, organizations such as Mind Medicine use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mind Medicine within its industry.Mind Medicine Manpower Efficiency
Return on Mind Medicine Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.5M | |
| Net Loss Per Executive | 7.2M | |
| Working Capital Per Employee | 3.3M | |
| Working Capital Per Executive | 16.2M |
Complementary Tools for Mind Stock analysis
When running Mind Medicine's price analysis, check to measure Mind Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mind Medicine is operating at the current time. Most of Mind Medicine's value examination focuses on studying past and present price action to predict the probability of Mind Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mind Medicine's price. Additionally, you may evaluate how the addition of Mind Medicine to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |